Publications by authors named "Preston Daniels"
Influenza is a major cause of morbidity and mortality for pediatric cancer patients. We review important aspects in the management of influenza, including virology, epidemiology, clinical presentation, diagnostic testing, and antiviral treatment. Topics that are addressed include optimal treatment of influenza in children with cancer as well as strategies for prevention.
View Article and Find Full Text PDFBreast cancer continues to have a high disease burden worldwide and presents an urgent need for novel therapeutic strategies to improve outcomes. The influenza vaccine offers a unique approach to enhance the anti-tumor immune response in patients with breast cancer. Our study explores the intratumoral use of the influenza vaccine in a triple-negative 4T1 mouse model of breast cancer.
View Article and Find Full Text PDFArticle Synopsis
- Recent research is shifting cancer treatment focus from direct viral effects to immune activation, utilizing oncotropic viruses like PV001-DV, a safe strain of Dengue virus known for its immune-boosting properties.
- The study demonstrated PV001-DV's ability to directly kill melanoma cells and enhance immune responses in patient blood cells, showing promising results in tumor cell death.
- These findings support further clinical trials of PV001-DV in advanced melanoma patients who have not responded to other treatments.
Article Synopsis
- Immunotherapies are increasingly used as primary treatments for advanced cancers, and this study explores how combining oncolytic virus (OV) and radiation therapy (RT) might enhance treatment outcomes.
- The research used mouse and human cancer cell lines, along with a skin cancer mouse model, showing that the combination therapy not only reduces tumor growth but also transforms 'cold' tumors into 'hot' tumors, which are more responsive to immune attacks.
- A patient with cutaneous squamous cell carcinoma experienced significant improvement after receiving the combined treatment, remaining free of disease progression for over 44 months, suggesting that the combination of OV, RT, and immune checkpoint inhibitors (ICIs) could be beneficial for patients with refractory cancers.